Xenon Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XENE research report →
Range $46 – $90
Price Chart
About the company
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada.
- CEO
- Ian C. Mortimer
- IPO
- 2014
- Employees
- 364
- HQ
- Burnaby, BC, CA
Get TickerSpark's AI analysis on XENE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.64B
- P/E
- -7.88
- Fwd P/E
- 1529.06
- PEG
- 0.42
- P/S
- 0.00
- P/B
- 3.22
- EV/EBITDA
- -8.20
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -39.80%
- ROIC
- -40.19%
Latest fiscal year · YoY change
- Revenue
- $7.50M+0.0%
- Gross Profit
- $4.96M+293.6%
- Op Income
- $-373,070,000
- Net Income
- $-345,910,000-47.6%
- EPS
- $-4.36-44.9%
- OCF Growth
- -53.9%
- FCF Growth
- -51.7%
- 52W High
- $72.66
- 52W Low
- $33.38
- 50D MA
- $39.45
- 200D MA
- $52.21
- Beta
- 0.60
- RSI (14)
- 41
- Avg Volume
- 1.68M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Xenon said it is nearing AZK approval and launch in epilepsy while accelerating its psychiatry and pain programs, with $1.2 billion in cash to support operations into 2029.· November 9, 2026
- AZK NDA is now filed, and management said the company is preparing for a potential U.S. approval and launch in focal seizures.
- X-TOLE2 remains the key efficacy anchor: management cited a 42.7% placebo-adjusted median percent change and said all four doses showed statistically significant seizure reductions versus placebo.
- The company completed enrollment in X-NOVA2 and moved top-line MDD data to December 2026 from Q1 2027, while keeping psychiatry development contingent on benefit-risk results.
- Xenon announced plans for a new Phase IIIb/IV X-FIRST study in 2027 to test AZK earlier in the epilepsy treatment paradigm.
- Pain programs advanced too: both XEN1701 and XEN1120 are moving toward Phase II proof-of-concept studies after Phase I data the company described as positive and well tolerated.
Xenon ended Q3 2026 with cash, cash equivalents, and marketable securities of $1.2 billion. Management said that, based on current operating plans, this cash balance funds operations into 2029. The call did not provide quarterly revenue, EPS, or gross margin figures. On guidance, the company said it expects multiple milestones over the next few months, including NDA acceptance, AES presentations, top-line X-NOVA2 data in December 2026, and progress toward Phase II proof-of-concept studies in pain in the first half of 2027.
Ian Mortimer framed the quarter as a step toward becoming a fully integrated neuroscience company, with the strongest emphasis on AZK in epilepsy, but also meaningful progress in psychiatry and pain. His tone was confident and forward-leaning, repeatedly pointing to strong prescriber feedback, a compelling epilepsy profile, and a launch buildout that is already underway. He also emphasized that psychiatry remains important, but the company needs the unblinded X-NOVA2 data before deciding next steps.
Tucker Kelly highlighted the company’s balance sheet, saying Xenon had $1.2 billion in cash, cash equivalents, and marketable securities at quarter-end and that this should fund operations into 2029. He said that cash position supports multiple AZK registration programs, the potential U.S. launch, and advancement of the pain pipeline and other early-stage R&D. He did not provide a detailed income statement update on the call, instead referring investors to the press release and 10-Q.
Analysts focused first on psychiatry: management said the X-NOVA2 data will be unblinded next month, then shared with the DSMB and FDA, and that any protocol changes or continuation decisions will follow those discussions. They also pressed on X-FIRST, asking whether the study could prove meaningful in an open-label setting and where it would sit in practice; management said it is designed to resemble real-world use in earlier-line patients, with general neurologists as a key audience. On pain, analysts asked whether the Nav1.7 data imply superiority and whether a reported syncope event was drug-related; management argued the receptor-occupancy data are highly encouraging and said the syncope case appeared linked to baseline orthostatic hypotension rather than drug exposure.
The bull case from the call is that AZK now has the regulatory filing, clinical data, and commercial preparation to become a real launch story in epilepsy. Management also sounded encouraged by strong physician and payer feedback, while the company’s cash balance gives it room to fund the launch and multiple pipeline shots on goal. The accelerated X-NOVA2 timeline and new pain data add optionality if those programs read out well.
The main risks are that psychiatry remains unresolved until X-NOVA2 is read out, and management explicitly said the program could stop if the data do not support future development. AZK’s broader expansion story also depends on proving value earlier in the treatment pathway with X-FIRST and other studies, which are still ahead. In pain, the programs are early and still need proof-of-concept validation, and management is only at the planning stage for chronic pain follow-on work.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.2%
- Shares Outstanding
- 98.28M
- Float Shares
- 92.62M
of shares held by institutions
325 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 11.55M | ▲ 1.91M |
| Blackrock, Inc. | 7.52M | ▲ 1.88M |
| Avoro Capital Advisors LLC | 5.78M | 0 |
| Polar Capital Holdings PLC | 4.57M | ▲ 165.24K |
| Driehaus Capital Management LLC | 4.42M | ▼ 73.10K |
| Jupiter Topco LLC | 4.19M | ▲ 4.19M |
| Janus Henderson Group Ltd. | 4.18M | ▲ 91.95K |
| Price T Rowe Associates Inc | 3.25M | ▲ 1.92M |
| Capital International Investors | 2.36M | ▼ 2.08K |
| T. Rowe Price Investment Management, Inc. | 2.17M | ▲ 1.22M |
| State Street Corp | 2.06M | ▲ 87.66K |
| Westfield Capital Management Co LP | 1.78M | ▲ 271.66K |
Held by 344 ETFs
Biggest fund positions in XENE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 15, 26 | Kelly Thomas Patrick | other | 7,500 |
| Oct 15, 26 | Kelly Thomas Patrick | other | 7,500 |
| Sep 30, 26 | Kelly Thomas Patrick | buy | 15,000 |
| Sep 30, 26 | MORTIMER IAN | buy | 30,000 |
| Sep 1, 26 | Svoronos Dawn | other | 5,144 |
| Sep 1, 26 | Svoronos Dawn | other | 5,144 |
| Aug 28, 26 | KENNEY CHRISTOPHER JOHN | sell | 6,368 |
| Aug 28, 26 | KENNEY CHRISTOPHER JOHN | sell | 700 |
| Aug 11, 26 | GANNON STEVEN | sell | 10,000 |
| Jun 5, 26 | PATOU GARY | sell | 1,322 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our XENE coverage
Recent articles, reports, and earnings notes.
No research on XENE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate XENE report →Reviewing Senti Biosciences (NASDAQ:SNTI) and Xenon Pharmaceuticals (NASDAQ:XENE)
defenseworld.net · Nov 19
Xenon Stock Rises 12% in the Past Month on Pipeline Progress
zacks.com · Nov 17
Xenon Pharmaceuticals Inc. (XENE) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
Xenon Pharmaceuticals Q3 Earnings Call Highlights
marketbeat.com · Nov 9
Xenon Reports Q3 2026 Financial Results and Provides Business Update
globenewswire.com · Nov 9
Xenon to Present at Upcoming Investor Conferences
globenewswire.com · Nov 3
Xenon to Report Q3 2026 Financial Results on November 9, 2026
globenewswire.com · Nov 2
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Oct 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.